BELIEVE: Phase III Study of Luspatercept vs Placebo in Beta-Thalassemia

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD Vamsidhar Velcheti, MD Released: September 15, 2021

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2021, from Clinical Care Options (CCO)

Jubilee Brown, MD Melissa M. Hardesty, MD, MPH Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Ursula Matulonis, MD David Scott Miller, MD, FACOG, FACS Released: September 15, 2021

Safety and efficacy analysis of larotrectinib in TRK fusion–positive lung cancer, from WCLC 2021 as reported by Clinical Care Options (CCO)

Subgroup analysis of IMower010 trial evaluating adjuvant atezolizumab vs best supportive care in patients with resected stage IB-IIIA NSCLC after adjuvant chemotherapy, from WCLC 2021 as reported by Clinical Care Options (CCO)